| Heading: |
Cystic Fibrosis: Pancreatic Enzyme Replacement Therapy |
| Question ID: |
1785895 |
| UIN: |
39263 |
| House: |
Commons |
| Date tabled: |
2025-03-18 |
| Asking Member ID: |
5338 |
| Asking Member display name: |
Terry Jermy
|
| Asking Member handle: |
cllrterryjermy
|
| Asking Member Twitter reference: |
@cllrterryjermy
|
| Member interest: |
false |
| Question text: |
To ask the Secretary of State for Health and Social Care, what he has made of the potential merits of using pancreatic enzyme replacement therapy for people with cystic fibrosis. |
| Is named day: |
false |
| Date of holding answer: |
|
| Date answered: |
2025-03-26 |
| Date answer corrected: |
|
| Is holding answer: |
false |
| Is correcting answer: |
false |
| Answering Member ID: |
4444 |
| Answering Member display name: |
Karin Smyth
|
| Answering Member handle: |
karinsmyth
|
| Answering Member Twitter reference: |
@karinsmyth
|
| Correcting Member ID: |
|
| Correcting Member display name: |
|
| Correcting Member handle: |
|
| Correcting Member Twitter reference: |
|
| Answer text: |
The National Institute for Health and Care Excellence (NICE) develops authoritative, evidence-based guidance for the National Health Service on best practice, based on an assessment of clinical and cost effectiveness. The NICE’s guideline on the diagnosis... |
| Original answer text: |
|
| Comparable answer text: |
|
| Answering body ID: |
17 |
| Answering body name: |
Department of Health and Social Care |
| Tweeted: |
true |